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Introduction:  
Converging lines of genetic, epidemiological and clinical evidence indicate that inflammatory 
pathways are altered in schizophrenia. Over twenty epidemiological studies show that 
people with a history of infection or autoimmune diseases have an increased risk of 
schizophrenia (Benros et al, 2014; Benros et al, 2011; Khandaker et al, 2012; Khandaker et 
al, 2013; Miller et al, 2013). Variants in genes of the immune pathways have also been 
associated with an increased risk of schizophrenia (Stefansson et al, 2009). Moreover, the 
largest genome-wide association study in schizophrenia to date found a highly significant 
association between risk of schizophrenia (Schizophrenia Working Group of the Psychiatric 
Genomics, 2014) and a locus linked to the major immunohistocampatibility complex with 
subsequent work implicating microglial and complement activation in this pathway (Sekar et 
al, 2016). Similarly, elevated levels of a number of immune markers have been observed in 
schizophrenia (Tourjman et al, 2013). Studies have repeatedly (although not invariably) 
shown that patients with schizophrenia have increased serum concentrations of pro-
inflammatory cytokines, including IL-1beta, IL-6, and TNF-α (Dickerson et al, 2016; 
Upthegrove et al, 2014). Meta-analyses show these are elevated in medication-naïve first 
episode patients (Upthegrove et al, 2014) and in later stages of illness(Dickerson et al, 
2016), with large effect sizes (eg: Hedge´s g >2.2 for IL-6 and >1.1 for IL-1ß) (Upthegrove et 
al, 2014). Moreover, studies of cerebrospinal fluid (CSF) have shown increased levels of pro-
inflammatory markers in schizophrenia patients when compared to healthy controls, 
including IL-1,,IL-6 and S100B (Sasayama et al, 2013; Schmitt et al, 2005; Schwieler et al, 
2015; Soderlund et al, 2009). While there is some evidence for increased inflammatory 
markers in blood and cerebrospinal fluid in schizophrenia, this cannot be taken to suggest 
neuro-inflammation. The evidence for increased cerebral activation of the immune system is 
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scarce. Post-mortem studies have demonstrated elevated markers for microglia, and 
morphological changes indicating microglial activation in schizophrenia patients (Bayer et al, 
1999; Radewicz et al, 2000; Trepanier et al, 2016) although this was not seen in all brain 
regions (Steiner et al, 2006) and there are still a large number of null studies (Trepanier et 
al., 2016). However, a recent meta-analysis of post-mortem studies by van Kesteren and 
colleagues confirmed overall increased microglia density in schizophrenia, together with 
increased concentrations of pro-inflammatory proteins (van Kesteren CMH, 2017). 
Microglia are the resident immune cells of the CNS and act as major mediators of 
neuroinflammation. In the healthy brain microglia retain a ͚quiescent͛ phenotype where 
processes extend through the local environment to detect context specific changes. In this 
stage, microglia cells produce neurotrophic factors, provide axonal guidance and regulate 
local cell proliferation. However, in response to inflammatory stimuli, the cells become 
activated, undergoing morphological changes and releasing pro-inflammatory cytokines. A 
number of risk factors for schizophrenia, notably pre-natal infection and psychosocial stress, 
are known to induce microglial activation (Calcia et al, 2016; Juckel et al, 2011). When 
microglia are activated, it increases the expression of the 18-kDa translocator protein (TSPO) 
(Cosenza-Nashat et al, 2009) . TSPO can be measured in vivo with Positron Emission 
Tomography (PET) radiotracers and so far a number of PET studies have investigated 
microglia activation in schizophrenia-spectrum disorders. However, findings have been 
inconsistent and so far they have only been partialy reviewed quantitatively (Plaven-Sigray 
et al, 2018) . We therefore aimed to synthesize PET imaging findings of microglial activation 
in patients with schizophrenia-spectrum disorders and healthy controls, and to discuss the 
implications of these findings in relation to both the pathophysiology of the disorder and 
drug development efforts. 
 4 
 
Methods:  
Data source and study selection 
The entire PubMed, EMBASE and PsycINFO databases were searched to identify 
manuscripts published from inception date until 12
th
 of January 2018. To be included in the 
meta-analysis, a study needed to report in vivo TSPO PET imaging data in patients with 
schizophrenia-spectrum disorders and in a healthy control group. All studies needed to 
report the mean and standard deviations for both groups (see figure 1).  
Data extraction 
The main outcome measure was the difference in the TSPO imaging index between patients 
with schizophrenia-spectrum disorders and healthy controls. For all studies we extracted the 
following variables: authors, year of publication, subject characteristics for the patient and 
healthy control group (group size, age, sex, diagnosis, duration of illness, antipsychotic 
medication, psychopathology rating scale scores), imaging characteristics (method, 
radiotracer), and modelling method. The estimation of pooled standard deviation was 
performed using the statstodo software (http://statstodo.com/ComMeans_Pgm.php). In 
order to extract data from studies where data was available only in a plot format we have 
used the plot digitizer software (http://plotdigitizer.sourceforge.net/).  
Data analysis 
The main outcome measure was the effect size determined using the TSPO tracer measure 
and quantified by either BPND, BP-P or VT in the the total gray matter in patients with 
schizophrenia-spectrum disorders and healthy controls using a random effects model. A 
minimum of three studies were required to run a meta-analysis. The group mean and error 
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measures were not reported by Banati and Hickie (2009) (Banati & Hickie, 2009) and, 
although we requested the data from the authors, we were unable to obtain them. 
Bloomfield et al 2016 reported the data in both VT and distribution volume ratio (DVR) 
(using a multivariate analysis approach, where VT in whole brain or cerebellum was used, 
along with age and TSPO genotype, as covariates in an ANCOVA producing a marginal 
mean). The distribution volume ratio method used in this study is not equivalent to the 
measures used in the other studies. Also Ottoy et al 2018 reported VT values only 
accounting for the vascular component (2TCM-1K) (Ottoy et al, 2018). In view of this we 
requested the data for this meta-analysis and both authors provided the VT values not 
accounting for the vascular component, determined in the same way as other studies (ie not 
covaried for age and gender). Therefore, the main analysis of VT values included 6 studies 
using the 2TCM model.  
A genetic variant at rs6971 in the TSPO gene, causing a non-conservative amino acid 
substitution, has been found to affect the binding of some TSPO PET tracers. (Owen et al, 
2012) Subjects who are homozygotes (LL) have low affinity binding (LAB) and have negligible 
TSPO binding in vivo. Those who are heterozygotes (HL) express both mixed affinity for 
TSPO (MAB), while those without the polymorphism (HH) have high affinity binding (HAB) 
for TSPO. (Guo et al, 2012) As on average MABs and HABs have a 22% difference in TSPO 
binding (Kreisl et al, 2013) we extracted the data for patients who are HABs and MABs 
separately to explore the effect of genotype in a sub-analysis.  
Publication bias was assessed using visual inspection of funnel plots as well as regression 
test. Where potential publication bias was suspected, trim and fill analysis was conducted to 
correct for putatively missing studies. Heterogeneity was estimated using the I
2
 value (I
2
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values <50% indicate low to moderate heterogeneity, whereas I
2
 >50% indicate moderate to 
high heterogeneity). Leave-one-out sensitivity analyses were conducted to investigate the 
potential effect of an individual study on the outcome measure. A p value <0.05 (2-tailed) 
was taken as a significance level. The statistical analysis of the extracted data was conducted 
using the R statistical programming language version 3.2.2 with the ͚metafor͛ package. 
Search strategy 
The Pubmed, EMBASE and PsycINFO databases were searched without language 
restrictions. The electronic search using EMBASE and PsycINFO were carried out together 
using Ovid. The following keywords were used: ͞(Positron Emission Tomography OR PET OR 
Single photon emission tomography OR SPET OR Single Photon Emission Computed 
Tomography OR SPECT) AND (schizophrenia OR schizophreniform OR psychosis) AND 
(microglia* OR microglia* activation OR TSPO OR Translocator protein OR peripheral 
benzodiazepine receptor OR peripheral benzodiazepine binding site)͟. Review papers were 
also screened to search for additional studies.  
Inclusion and exclusion criteria 
The inclusion criteria were: original studies in (1) patients with a diagnosis of schizophrenia 
or related psychotic diagnoses (including schizophreniform disorder; psychotic disorder not 
otherwise specified, brief psychosis) 2) reporting PET measures using a TSPO specific ligand 
and 3) reporting data for the whole gray matter or gray matter regions. Studies that did not 
have a control group were excluded. Where there was sample overlap between studies we 
included the largest one and excluded the other to avoid double counting.  
Outcome measures 
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The primary outcome measure was the effect size for the difference in TSPO PET measure in 
total gray matter between patients with schizophrenia-spectrum disorders and healthy 
controls. Where several studies only reported values for gray matter sub-regions, we 
averaged the gray matter regions to estimate the value for the whole gray matter. The PET 
studies predominantly reported the outcome either as binding potential (BP) or volume of 
distribution (VT). As these give different information we conducted separate meta-analyses 
of these outcomes. The studies that used binding potential as an outcome measure have 
used either values obtained using microparameters from SRTM (Di Biase et al, 2017; Holmes 
et al, 2016; van der Doef et al, 2016), but Van Berckel et al. 2008 (van Berckel et al, 2008) 
and Doorduin et al., 2009 (Doorduin et al, 2009) have calculated binding potential 
using microparameters derived from 2TCM model. Despite this difference, the results are 
comparable as reviewed in PET receptor imaging consensus (Innis et al, 2007). 
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Results 
 
TSPO binding  
There were a total of 12 studies measuring TSPO tracer binding in 190 patients with 
schizophrenia-spectrum disorders and 200 healthy controls. Five of these studies were in 
chronic patients, seven in patients within the first five years of diagnosis, and 2 studies also 
included subjects at ultra-high risk for psychosis. See Table 1 for a summary of sample and 
study method characteristics. The rationale behind individual study exclusion is documented 
in supplementary information.   
Studies reporting outcome as binding potential (BP):  
Six studies reported outcome measures as BP. Our results showed that BP was significantly 
elevated in patients with schizophrenia when compared to healthy controls with an effect 
size of 0.31 [Hedges g= 0.31; z= 2.1; p= 0.03; 95% confidence interval (CI): 0.02-0.6] (Figure 
2). The I
2 
test revealed low heterogeneity (I
2 
= 0.58%; 95% CI: 0-79%). Visual inspection of 
the funnel plot suggested asymmetry (Supplementary figure 1). The regression test was 
significant (t=4.5; df=4; p=0.01). The trim and fill analysis showed three putatively missing 
studies on the left side. The results were not significant after correcting for these studies 
(Hedges g= 0.13; z= 0.96; p= 0.34; 95% CI: -0.14-0.4). The results were significant in 2 out of 
6 in the leave one out analysis, with effect sizes varying from 0.27 to 0.47. Five out of the six 
studies used the [
11
C]-PK11195 ligand, with the sub-analysis of these studies revealing a 
significant elevation of BP in patients with schizophrenia with an effect size of 0.35 (CI: 0.01-
0.7; p= 0.046) (Supplementary figure 2).  
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Studies reporting the outcome as volume of distribution (VT):  
Six studies reported the outcome measure as VT. Figure 3 shows that there was no 
difference in VT in patients with schizophrenia when compared healthy controls (Hedges g= -
0.22; p=0.296; CI: -0.64- 0.19). The I
2 
test revealed moderate-high heterogeneity (I
2 
= 53%; 
95% CI: 0-92%). Visual inspection of funnel plot suggested asymmetry (Supplementary figure 
3). However, the regression test was not significant (t=-0.73; df=4; p=0.5). Trim and fill 
analysis showed two missing studies in the right side. The effect sizes varied from -0.08 to -
0.37 in the leave one out analysis. We extracted data for high (HAB) and mixed affinity 
binders (MAB) separately from these studies to conduct a sub-analysis stratified by 
genotype. Bloomfield et al reported only one patient who was a MAB, precluding accurate 
estimation of the effect size. Thus this study was not included in the sub-analysis of MAB 
subjects (Bloomfield et al, 2016b). There was no significant difference between patients and 
controls in the high affinity binder sub-analyses (effect size -0.27; p=0.19; CI: -0.68 to 0.13). 
However, there was a significant difference in the mixed affinity binding (effect size -0.56; 
p= 0.03; CI: -1.08 to - 0.03).  
Discussion: 
Our main findings are that TSPO PET tracer binding is significantly elevated in patients with 
schizophrenia relative to controls when binding potential (BP) is used as an outcome 
measure, with a small to moderate effect size (Hedge͛s g= 0.31; p=0.03), but there is no 
significant difference when the tracer volume of distribution (VT) is used as the outcome 
measure (Hedge͛s g= -0.22; p=0.296). In the following section, we consider methodological 
factors and the implications of our findings. 
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Methodological considerations 
We identified potential publication bias for both outcome measures and in the case of BP 
meta-analysis the results were no longer significant when adjusted for putative missing 
studies, which if present could potentially affect our findings. Heterogeneity was low for 
those studies that used BP as an outcome measure and moderate to high in those that used 
VT as an outcome measure. For this meta-analysis we used a random effects model, which is 
robust to between study variations. We acknowledge that 4 of the 12 studies used in this 
meta-analysis analysed patients with schizophreniform disorder, psychotic disorder not 
otherwise specified, and brief psychosis as well as patients with schizophrenia (Collste et al., 
2017, Doorduin et al., 2009, Hafizi et al., 2017, van der Doef et al., 2016). Two of the studies 
do not provide a break-down of individual patient participant diagnoses, other than to 
classify patients as presenting with first episode psychosis (Hafizi et al., 2017, van der Doef 
et al., 2016), thus up to 52/190 (27%) of patients included in the meta-analysis are defined 
as presenting with a schizophreniform disorder, rather than a definitive diagnosis of 
schizophrenia. Therefore our results could be influenced by the inclusion of other psychotic 
disorders, although the low heterogeneity observed for the meta-analysis using BP as an 
outcome measure at least suggest that including individuals with broader psychotic 
diagnoses alongside schizophrenia did not have a major impact on the results. Five out of 
the six studies included in the BP meta-analysis used the first generation tracer [
11
C]-
PK11195, whereas the VT studies used second generation tracers. Thus the difference 
between BP and VT outcomes could reflect tracer differences, as [
11
C]-PK11195 is known to 
have low brain penetration, and high non-specific binding, which is a significant limitation of 
this tracer relative to the second generation tracers (Fujita et al, 2008). However, although 
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the outcome of the BP study that used a different tracer ([
11
C]-DAA1106) is negative, the 
results using this tracer are not an outlier, suggesting findings may not entirely be 
accounted for by tracer differences. It has been suggested that TSPO expression may change 
during the course of the disorder, which could account for the differences in findings 
between studies (Notter et al, 2018). However, a recent study by Di Biase using BP as an 
outcome measure showed no differences between at risk mental state individuals, recent 
onset schizophrenia and chronic schizophrenia (Di Biase et al, 2017), and our BP and VT 
meta-analyses both included studies of chronic and recent onset illness, suggesting that this 
does not clearly explain the differences between our BP and VT findings. Ultimately 
longitudinal studies in patients are required to determine if there are changes during the 
course of the illness. Other differences between the studies using BP and VT, such as 
differences in tracer and modeling approaches, could contribute to the differences between 
our BP and VT meta-analytic findings. Another potential issue is that not all studies 
accounted for a genetic variant at rs6971 in the TSPO gene. Six out of the 12 studies 
included in this meta-analysis did not report genotyping (Di Biase et al, 2017; Doorduin et al, 
2009; Holmes et al, 2016; Takano et al, 2010; van Berckel et al, 2008; van der Doef et al, 
2016). Out of these 6 studies, 5 used the [
11
C]-PK11195 tracer while one study used the 
tracer [
11
C]-DAA1106. However, genotyping has been shown not to be necessary in studies 
using [
11
C]-PK11195, as in-vitro studies have shown that this tracer binds to a different site 
on the TSPO to the locus affected by the rs6971 variant, and, consequently, there is no 
difference in affinity to TSPO between high affinity and low affinity binders (Owen et al, 
2012). However, our sub-analyses for the other tracers stratified by genotype showed group 
differences only remained significant in the mixed affinity binding groups. We caution 
against over-interpretation of this finding given the small sample, but suggest it warrants 
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further investigation. Another potential methodological limitation is that a number of 
studies did not account for partial volume effects. However, as brain volumes tend to be 
reduced in schizophrenia, partial volume effects would not explain the elevation in BP and, 
if anything, would tend to reduce the effect size, which means our results may 
underestimate the true effect. Aditionally, in those cases where total gray matter TSPO 
levels were not available, we have averaged the gray matter regions to estimate the value 
for the whole gray matter. Although this is a common procedure in PET meta-analyses 
(Ashok et al, 2017; Howes et al, 2012; Kambeitz et al, 2014) it can constitute a pontential 
limitation of this study. Finally, most of the studies in this meta-analysis included patients 
who were being treated with antipsychotics. Preclinical studies in vitro have found 
antipsychotic treatment to reduce microglial activation, (Zheng et al, 2008) although recent 
in vivo work has found an increase after olanzapine, but a reduction with risperidone. (Cotel 
et al, 2015; Crum et al, 2016; Zhu et al, 2014) Critically, none of these studies measured 
TSPO levels, so it remains unknown if antipsychotics alter TSPO expression. Interestingly, 
bot the studies by Holmes and Di Biase showed that unmedicated patients have lower BP 
when compared to antipsychotic-treated patients and healthy controls (Di Biase et al, 2017; 
Holmes et al, 2016). However, this analysis was based only on data provided by 12 patients 
and further work is thus needed to understand whether antipsychotic treatment could have 
affected our findings. 
Interpretation of findings 
The non-displaceable binding potential (BPND) measures the tracer binding in the tissue of 
interest relative to another brain region selected to have negligible specific binding, to give 
specific binding in the region of interest (Mintun et al, 1984). An issue for the measurement 
of BPND is that there is no brain region with negligible TSPO expression, and consequently no 
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ideal reference region for TSPO tracers. (Bloomfield et al, 2016a; Narendran & Frankle, 
2016; Turkheimer et al, 2015) Thus the elevation in BP we report could reflect an increase in 
specific binding and/or a reduction in non-specific binding in gray matter relative to the 
reference brain tissue. In contrast, the volume of distribution (VT) measures the total 
amount of tracer in the brain region relative to that in the blood. (Innis et al, 2007) Volume 
of distribution is generally the preferred method of quantification of PET tracers where 
there is no reference region but, critically for group comparisons, assumes blood tracer 
binding is unaltered between groups. (Innis et al, 2007) However, TSPO tracers may bind to 
a number of sites in the blood, including acute phase and inflammatory plasma proteins, 
such as α1-acid glycoprotein (AGP) that are known to be elevated in schizophrenia. (Telford 
et al, 2012; Tourjman et al, 2013) As TSPO tracers bind to AGP, (Lockhart et al, 2003) there is 
the potential for a systematic bias between patients and controls that could affect the 
quantification of VT, and potentially mask an elevation in the patients brain as compared to 
controls. There is inconsistency in findings in schizophrenia, with one study showing 
elevation in the plasma concentration levels of [
11
C]-PBR28 in patients with schizophrenia 
relative to controls (Bloomfield et al, 2016a), whilst two others using [18F]-FEPPA and [11C]-
PBR28 show no differences in plasma concentration levels (Collste et al, 2017; Hafizi et al, 
2016) . There is also evidence for reduced levels of binding of TSPO tracers to TSPO 
(previously known as the peripheral benzodiazepine receptor) on platelets in schizophrenia, 
with reductions of ~30 % reported in some studies, (Gavish et al, 1986; Weizman et al, 
1986), although potentially only in certain sub-types of schizophrenia (Wodarz et al, 1998). 
Thus it is possible that changes in either plasma protein binding and/or platelet binding 
could systematically affect VT values in the disorder, but it should be recognised that there is 
no direct evidence that plasma binding alters VT values in humans (Cumming et al, 2018). 
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Importantly, in a recent study where protein binding was measured, no significant group 
differences between drug-naive first-episode psychosis patients and healthy controls were 
observed, suggesting that VT changes are not explained by an effect of protein binding 
(Collste et al, 2017). Further studies are thus needed to clarify if there is an impact of this on 
the measurement of VT in schizophrenia. Nevertheless, whilst this is a potential concern for 
studies using VT as the outcome measure, blood binding should not affect the studies that 
use a ratio approach, as these methods report tracer uptake relative to another brain region 
rather than blood. Furthermore, TSPO is expressed on the endothelial cells of brain blood 
vessels as well as on the outer layer of mitochondria in microglia, (Rizzo et al, 2014) and 
both can be accounted for in the PET analysis. (Turkheimer et al, 2015) Few of the studies 
included in this meta-analysis have accounted for endothelial binding. In view of this, in our 
meta-analysis we have included the results not accounting for this compartment. A separate 
meta-analysis was conducted including the data accounting for the endothelial binding and 
the results were very similar suggesting this is unlikely to be a major influence on our 
findings. 
Taken together our meta-analytic findings suggest an elevation in TSPO tracer binding in 
total gray matter relative to other brain tissue, but not relative to blood, with the caveat 
that the relative increase is largely based on studies using PK11195, which has a lower 
specific signal. Thus, this could reflect an increase in TSPO in gray matter or a reduction in 
TSPO in the reference region, or altered non-specific binding in the brain (Cumming et al, 
2018). It should also be noted that reductions in TSPO have been reported in some pro-
inflammatory states (Narayan et al, 2017). Finally, TSPO may also be expressed on 
astrocytes (Cosenza-Nashat et al, 2009). Whilst altered TSPO expression on astrocytes may 
contribute to the differences, the post-mortem findings of unaltered astrocytic but elevated 
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microglial markers (Trepanier et al, 2016), including elevated TSPO binding (Kreisl et al, 
2013),  are more suggestive of a microglia activity increase in schizophrenia. However, until 
further work has been conducted to determine if changes in translocator protein expression 
in schizophrenia are specific to microglia, conclusions about the specificity of changes to 
microglia should be treated cautiously. 
Implications of our findings and future directions: 
Our different findings depending on the outcome measure used point towards the existence 
of potential methodological problems in TSPO imaging, raising questions over the 
interpretation of the elevation in gray matter TSPO binding relative to a reference region in 
patients with schizophrenia when compared to healthy controls. A recent individual 
participant data (IPD) meta-analaysis of second-generation radioligand studies, with VT as 
the outcome measure, showed a reduction in VT in patients relative to healthy controls 
(Plaven-Sigray et al, 2018). Although these results seems to be in contrast to the absence of 
differences in VT in our meta-analysis, our meta-analysis included one more second-
generation study showing no differences in VT between schizophrenia patients and healthy 
controls (Ottoy et al, 2018), which may justify the differences in results between meta-
analysis. Ultimately the definitive test of the importance of TSPO and/or microglia activation 
in schizophrenia will be to pharmacologically target them with a selective drug or 
monoclonal antibody combined with PET imaging to confirm target engagement and 
evaluate the relationship between change in microglial activation and symptomatic 
improvement. Secondly, it remains to be determined if microglia activity is altered across 
the different stages of the disorder. Epidemiological and preclinical evidence which indicates 
that neuroinflammation in utero and early development may predispose to schizophrenia, 
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(Meyer, 2013) However, the PET results have been inconsistent, with one study using the 
tracer [11C]-PBR28 showing an elevation in relative TSPO binding in people at ultra high risk 
of psychosis using the ratio but not with the VT approach (Bloomfield et al, 2016b), while 
two studies using VT as the outcome measure, using the tracer [18F]-FEPPA and [11C]-
PK11195, showed no differences in TSPO binding between healthy controls and in 
individuals at ultra high risk of psychosis for psychosis (Di Biase et al, 2017; Hafizi et al, 
2016). Unfortunately, there were not sufficient studies to proceed with a sub-analysis of 
studies conducted in the early phase of illness. Future research should focus on at risk 
mental state individuals and early in the development of the illness and use longitudinal 
designs to determine the role of microglial activity in the different stages of the disorder. 
Ideally, these studies should be conducted before antipsychotic medication initiation, as it 
would also help to clarify the potential role of antipsychotics in microglia activity. 
Interestingly, it has been shown that pro-inflammatory cytokines are elevated in first 
episode patients who do not respond to antipsychotic treatment relative to those who do 
respond, (Mondelli et al, 2015) which suggests that increases in microglia activity may be 
specific to a sub-group of patients, consistent with neurobiological syb-types of 
schizophrenia. (Howes & Kapur, 2014) Studies that focus on patients that do not respond to 
conventional antipsychotic medication should be able to shed light on this topic. When 
interpreting our results is also important to note that this meta-analysis focused on total 
gray matter TSPO binding, and there was insufficient data for a meta-analysis of specific 
brain regions. Although TSPO is ubiquitous and expressed across the whole brain, we cannot 
exclude that microglia activation in schizophrenia is differentially expressed in specific 
regions within the brain. Indeed, early studies by Doorduin et al (2009) (Doorduin et al, 
2009) and van Berckel et al (2008) (van Berckel et al, 2008) suggest increased TSPO binding 
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in the medial temporal cortex, and Bloomfield et al (2016) (Bloomfield et al, 2016b) using 
the DVR approach also found evidence of this in people at ultra high risk of psychosis. 
Finally, future studies are needed to address the methodological issues and sources of 
variance discussed above. This could be potentially achieved by obtaining individual patient 
data from each individual study and applying both ratio and volume of distribution models 
to determine if PET modeling or study differences drive the opposing BP and volume of 
distribution findings. In addition, we recommend that new studies present results for both 
modelling approaches so that consistency of findings can be compared and support future 
meta-analysis, while the role of vascular binding in PET TSPO quantification should be 
clarified.  
Conclusion  
In conclusion, there is evidence for a moderate effect size elevation in TSPO tracer binding 
in gray matter in schizophrenia spectrum disorders when using BP as an outcome measure, 
but no changes when VT is the outcome measure used. These results suggest that potential 
methodological differences between TSPO studies need to be accounted for and addressed 
in future studies and keep open the discussion over the existence of an increase in microglia 
activity in patients with schizophrenia spectrum disorders. 
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Figure 1. Flowchart showing the inclusion of studies for the meta-analysis  
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Figure 2:  Forest plot showing the effect sizes for in vivo microglia measures in 
schizophrenia patients compared to controls as measured by translocator protein binding 
potential (BP) in total gray matter. There was a significant elevation in schizophrenia with 
an effect size=0.31 (p=0.03). 
  
  
 3 
Figure 3: Forest plot showing effect sizes for in vivo microglia measures in schizophrenia patients 
compared to controls as measured by volume of distribution of translocator radiotracer (VT) in 
total gray matter. There were no significant changes in patients compared to controls (effect size=-
0.22, p=0.296). 
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Table 1: Subject and methodological characteristics of the in vivo imaging studies of TSPO binding in schizophrenia compared to healthy 
controls (BP=6 ; VT=6) 
Author 
Year 
Patients
/ 
Controls 
(n) 
Patient 
Age 
mean 
(SD) 
years 
Diagnosis Duration 
of Illness 
mean (SD) 
years 
Current 
antipsychotic 
treatment? 
Region(s) of interest (ROI) Tracer Genotyping Outcome 
Measures 
Results in patients 
compared to 
controls 
van Berckel 
et al., 2008  
10/10 24 (2) Recent-onset 
Schizophrenia  
(< 5 years of 
illness) 
3.1 (1.7) Yes 
 
Total Gray Matter 
 
[
11
C]-
PK11195 
No BP-P ↑ 
Doorduin et 
al., 2009 
7/8 31.2 
(7.2) 
Recent-onset 
Schizophrenia  
(< 5 years of 
illness)/Psychoti
c disorder not 
otherwise 
specified 
5.4 (5.4) Yes 
 
Total Gray Matter 
Frontal Cx / Occipital Cx / Temporal Cx 
/ Parietal Cx / Basal ganglia / Thalamus 
/ Hippocampus / Midbrain / 
Cerebellum / Pons  
[
11
C]-
PK11195 
No BP ↑ ;Hippocaŵpus Ϳ 
 
↔ (total gray 
matter and all ROI) 
 
Takano et 
al., 2010 
14/14 43.8 
(7.4) 
Chronic 
Schizophrenia 
18.8 (12.2) Yes 
 
Total Cortical Regions 
Medial frontal cortex, Dorsolateral 
frontal cortex, Medial Temporal 
Cortex, lateral temporal cortex, 
parietal cortex, occipital cortex, 
thalamus, striatum, cerebellum, 
anterior cingulate cortex, and 
posterior cingulate cortex 
[
11
C]-
DAA1106 
No BPND ↔ ;all regioŶsͿ 
Kenk et al., 
2015 
18/27 42.6 
(14.1) 
Chronic 
Schizophrenia 
14.8 (8.8) Yes 
 
Hippocampus / mPFC Cx / Temporal Cx 
/ DLPFC Cx / V Striatum / Corpus 
Callosum / Cingulum / SLF / PLIC 
[
18
F]-
FEPPA 
Yes VT ↔ ;all regioŶsͿ 
Bloomfield 
et al., 2016 
14/14 
 
24.3 
(5.4) 
Ultra high risk 
for psychosis 
 
N/A No 
 
Total Gray Matter/ Frontal Cx  / 
Temporal / Cerebellum / Brain Stem 
  
[
11
C]-
PBR28 
Yes DVR 
VT  
DVR: ↑ ;total gray 
matter, frontal Cx, 
temporal Cx); 
↔ ;all other 
regions) 
VT: ↔ ;all regioŶsͿ 
 3 
14/14 47.0 
(9.3) 
Chronic 
Schizophrenia 
Not 
specified 
Yes 
 
Total Gray Matter/ Frontal Cx / 
Temporal Cx / Cerebellum / Brain Stem 
 
DVR: ↑ ;total gray 
matter, frontal Cx, 
temporal Cx);  
↔ ;all other 
regions) 
VT: ↔ ;all regioŶsͿ 
Hafizi et al., 
2016 
19/20 27.5 
(6.7) 
First episode  
Psychosis: 
schizophrenifor
m disorder / 
delusional 
disorder / 
schizophrenia / 
psychosis NOS 
2.8 (3.3) No Whole Brain 
Total Gray Matter 
DLPFC / mPFC / Temporal Cx / 
Hippocampus 
[
18
F]-
FEPPA 
Yes VT  
DVR 
↔ ;all regioŶsͿ 
van der 
Doef et al., 
2016 
19/17 26 (4) First episode 
psychosis 
(< 5 years of 
illness) 
 
1.3 (1.1) Yes 
 
Total gray matter 
Frontal Cx / Temporal Cx / 
Parietal Cx / Striatum / Thalamus 
[
11
C]-
PK11195 
No BPND ↔ ;all regioŶsͿ 
Coughlin et 
al., 2016 
12/14 24.1 
(3.1) 
Recent-onset 
Schizophrenia  
(< 5 years of 
illness) 
2.2 (1.4) Yes 
 
Total gray matter 
Insula Cx / Cingulate Cx / Parietal Cx / 
Frontal Cx / Temporal Cx / Occipital Cx 
/ Hippocampus / Amygdala 
[
11
C]- 
DPA-713 
Yes VT ↔ ;all regioŶsͿ 
Holmes et 
al., 2016 
8/16 
 
33 (9) Schizophrenia 15 (7) Yes 
 
DLPFC / VLPFC / OFC / Anterior 
Cingulate Cx / Parietal Cx 
[
11
C]-
PK11195 
No BPND ↑ DLPFC, VLPFC 
and ACC 
↔ (all other 
regions) 
8/16 
(shared  
control 
group) 
Schizophrenia 4 (2) No ↔ ;all other 
regions) 
Collste et 
al., 2017 
16/16 28.5 
(8.4) 
First episode  
psychosis: 
schizophrenia/ 
schizophrenifor
m psychosis/ 
psychosis NOS 
/brief psychosis 
7.9 (9.6) No Total gray matter 
White Matter / frontal Cx / temporal 
Cx / Hippocampus 
 
[
11
C]-
PBR28 
Yes VT  (total gray 
matter, frontal Cx, 
temporal Cx,  
Hippocampus) 
↔ (white matter) 
 4 
Di Biase et 
al., 2017 
18/15 
 
20.6 
(5.5) 
Recent-onset  
Schizophrenia 
1.5 (1.0) Yes 
 
 
Dorsal Frontal Cx / Orbital Frontal Cx / 
Anterior Cingulate Cx / Medial 
Temporal Cx / Thalamus / insular Cx   
[
11
C]-
PK11195 
No BPND ↔ ;all regioŶsͿ 
15/12 35.2 
(6.6) 
Chronic 
Schizophrenia 
13.6 (8.8) Yes 
 
Dorsal Frontal Cx / Orbital Frontal Cx / 
Anterior Cingulate Cx / Medial 
Temporal Cx / Thalamus / insular Cx   
[
11
C]-
PK11195 
No BPND ↔ ;all regioŶsͿ 
Ottoy et al., 
2018  
11/17 30.0 
(7.0) 
Chronic 
Schizophrenia 
N/A Yes 
 
Cortical Gray Matter / Cortical White 
Matter / Cerebellum / Brainstem / 
Thalamus / Basal Ganglia / 
Hippocampus / Amygdala 
 
[
18
F]-
PBR111 
Yes 
 
VT ↔ ;all regioŶsͿ 
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Supplementary Material 
 
Supplementary figure 1: Funnel plot of studies reporting outcome measures with BP 
method 
 
Supplementary figure 2: Forest plot of studies which used [
11
C]-PK11195 ligand 
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Supplementary figure 3: Funnel plot of studies reporting outcome measures with VT 
method 
 
 
 
Supplementary figure 4: Forest plot of studies reporting outcome measures with the VT 
method in mixed affinity binders 
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Supplementary figure 5: Forest plot of studies reporting outcome measures with the VT 
method in high affinity binders 
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